Program
Edaravone
Also written as “MT-1186”, “MCI-186” and “Continuous infusion high-dose MCI-186”.
Its studies are mostly in Amyotrophic Lateral Sclerosis · Ischemic Stroke · Cerebral Infarction · Renal Insufficiency · Ischemia, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shionogi | 230 open or running | phase 4since Sep 12, 2005 | Sep 12, 2005 | none ahead |
| Jiangsu HengRui Medicine | 10 open or running | phase 1since Jul 16, 2025 | Jul 16, 2025 | none ahead |
| Nanjing Yoko Biomedical | 10 open or running | phase 1since Dec 17, 2019 | Dec 17, 2019 | none ahead |
| Shanghai Auzone Biological Technology | 10 open or running | phase 1since Oct 16, 2023 | Oct 16, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 9 studies since Sep 12, 2005.
- Aug 27, 2018Phase 1 study in Severe Hepatic ImpairmentShionogi · NCT03664544 · 12 enrolled · Czechia, Hungary, Slovakia
- Jul 10, 2019Phase 1 study in Healthy Adult SubjectsShionogi · NCT04029090 · 27 enrolled · Japan
- Nov 13, 2019Phase 3 study in ALSShionogi · NCT04165824 · 185 enrolled · United States, Canada, France and more
- Nov 22, 2019Phase 1 study in Japanese Patients With ALSShionogi · NCT04176224 · 9 enrolled · Japan
- Dec 17, 2019Nanjing Yoko Biomedical's first study: phase 1 study in Drug-drug InteractionNew to Nanjing Yoko BiomedicalNanjing Yoko Biomedical · NCT04218513 · 24 enrolled · China
- Jan 23, 2020Phase 1 study in Japanese Patients With ALSShionogi · NCT04254913 · 6 enrolled · Japan
- Jul 17, 20203 phase 1 studies in Healthy Adult SubjectsShionogi · NCT04481789, NCT04481750, NCT04493281
- Sep 23, 20202 phase 3 studiesShionogi · NCT04569084, NCT04577404
- Feb 25, 2021Phase 1 study in Healthy Adult SubjectsShionogi · NCT04776135 · 36 enrolled · Japan
- Nov 28, 2021Phase 3 study in ALSShionogi · NCT05151471 · 202 enrolled · United States, Canada, Germany and more
- Apr 19, 2022Phase 1 study in Healthy Adult SubjectsShionogi · NCT05342597 · 16 enrolled · Japan
- Oct 2, 2022Phase 3 study in ALSShionogi · NCT05568615 · 15 enrolled · Japan
- Oct 16, 2023Shanghai Auzone Biological Technology's first study: phase 1 study in Healthy Adult SubjectsNew to Shanghai Auzone Biological TechnologyShanghai Auzone Biological Technology · NCT06107205 · 29 enrolled · United States
- Jul 16, 2025Jiangsu HengRui Medicine's first study: phase 1 study in Acute Ischemia StrokeNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT07083362 · 83 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 26 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07083362Acute Ischemia Stroke · China | 1 | Completed | Jiangsu HengRui Medicine | Jan 12, 2026 | 83 |
| NCT06107205Healthy Adult Subjects · United States | 1 | Completed | Shanghai Auzone Biological Technology | Dec 14, 2023 | 29 |
| NCT05568615ALS · Japan | 3 | Completed | Shionogi | Jun 27, 2023 | 15 |
| NCT05342597Healthy Adult Subjects · Japan | 1 | Completed | Shionogi | Jul 24, 2019 | 16 |
| NCT05151471ALS · United States, Canada, Germany and more | 3 | Terminated | Shionogi | Sep 29, 2023 | 202 |
| NCT04776135Healthy Adult Subjects · Japan | 1 | Completed | Shionogi | Apr 1, 2021 | 36 |
| NCT04577404Amyotrophic Lateral Sclerosis · United States, Canada, France and more | 3 | Completed | Shionogi | Aug 9, 2023 | 124 |
| NCT04569084ALS · United States, Canada, Germany and more | 3 | Terminated | Shionogi | Sep 29, 2023 | 384 |
| NCT04493281Healthy Adult Subjects · Japan | 1 | Completed | Shionogi | Apr 21, 2019 | 42 |
| NCT04481789Healthy Adult Subjects · Japan | 1 | Completed | Shionogi | Dec 20, 2018 | 84 |
| NCT04481750Healthy Adult Subjects · Japan | 1 | Completed | Shionogi | Aug 3, 2018 | 74 |
| NCT04254913Japanese Patients With ALS · Japan | 1 | Completed | Shionogi | Apr 16, 2020 | 6 |
| NCT04218513Drug-drug Interaction · China | 1 | Completed | Nanjing Yoko Biomedical | May 31, 2019 | 24 |
| NCT04176224Japanese Patients With ALS · Japan | 1 | Completed | Shionogi | Sep 4, 2019 | 9 |
| NCT04165824ALS · United States, Canada, France and more | 3 | Completed | Shionogi | Oct 7, 2021 | 185 |
| NCT04029090Healthy Adult Subjects · Japan | 1 | Completed | Shionogi | Oct 20, 2018 | 27 |
| NCT03664544Severe Hepatic Impairment · Czechia, Hungary, Slovakia | 1 | Completed | Shionogi | Mar 25, 2019 | 12 |
| NCT03346538Ischemic Stroke · Japan | 2 | Terminated | Shionogi | May 14, 2018 | 17 |
| NCT03289234Hepatic Impairment · Japan | 1 | Completed | Shionogi | Jul 20, 2018 | 22 |
| NCT03289208Renal Insufficiency · Japan | 1 | Completed | Shionogi | Apr 16, 2018 | 30 |
| NCT01492686Amyotrophic Lateral Sclerosis · Japan | 3 | Completed | Shionogi | Sep 30, 2014 | 137 |
| NCT00821821Ischemic Stroke · Finland, Netherlands, United Kingdom | 2 | Completed | Shionogi | Nov 30, 2010 | 36 |
| NCT00424463Amyotrophic Lateral Sclerosis · Japan | 3 | Completed | Shionogi | May 31, 2009 | 181 |
| NCT00415519Amyotrophic Lateral Sclerosis | 3 | Completed | Shionogi | Jul 31, 2008 | 25 |
| NCT00330681Amyotrophic Lateral Sclerosis | 3 | Completed | Shionogi | Sep 30, 2008 | 206 |
| NCT00200356Cerebral Infarction | 4 | Completed | Shionogi | Oct 31, 2006 | 401 |
How it is read
Names in the registry
- “MT-1186”, 12 entries
- “MCI-186”, 10 entries
- “Edaravone”, 1 entry
- “Continuous infusion high-dose MCI-186”, 1 entry
- “Continuous infusion low-dose MCI-186”, 1 entry
Codes read as this program: MT1186, MCI186.
Conditions, from the studies’ own filings
- Amyotrophic Lateral Sclerosis, 5 studies
- Ischemic Stroke, 2 studies
- Cerebral Infarction, 1 study
- Renal Insufficiency, 1 study
- Ischemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.